Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 21 , ISSUE 9 ( 2017 ) > List of Articles

RESEARCH ARTICLE

Vasopressin in septic shock; assessment of sepsis biomarkers: A randomized, controlled trial

Arezoo Ahmadi, Elchin Barzegar, Masoumeh Nouri, Sarah Mousavi, Mojtaba Mojtahedzadeh

Keywords : Sepsis biomarkers, septic shock, vasopressin

Citation Information : Ahmadi A, Barzegar E, Nouri M, Mousavi S, Mojtahedzadeh M. Vasopressin in septic shock; assessment of sepsis biomarkers: A randomized, controlled trial. Indian J Crit Care Med 2017; 21 (9):578-584.

DOI: 10.4103/ijccm.IJCCM_258_17

License: CC BY-ND 3.0

Published Online: 01-09-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background and Aims: Vasopressin (VP) in sepsis apart from vasoconstrictive effect may have some immunomodulatory effects. The aim of this study was to evaluate the effect of VP on different aspect of sepsis by measuring of sepsis biomarkers. Materials and Methods: In this trial, a total number of 42 septic shock patients were included. The first group received norepinephrine (NE) infusion to reach the target mean arterial pressure (MAP) of ≥ 65 mm Hg and the second group received arginine vasopressin (AVP) infusion in addition to NE. Serum lactate, C-reactive protein (CRP), interleukin-6 (IL-6), IL-10, pentraxin 3 (PTX3), angiopoietin 1 and 2 (Ang 1 and 2) levels were assessed. Results: Level of IL-6 and IL-10 decreased, but there was no significant difference between the two groups after 48 h. CRP and PTX3 levels were not also significantly different between groups. Although Angs were not statistically different, there was a trend toward higher Ang-1 in and lower Ang 2 in AVP group after 24 and 48 h. In addition, lactate level did not differ between NE and AVP groups. There was no interaction between VP and hydrocortisone use on IL-6, IL-10, and PTX3, but a significant statistical interaction on Ang 1 and Ang 2 were observed. Conclusions: Although analysis of sepsis biomarkers showed no significant difference between two groups, no immunomodulatory effect for VP alone, subgroup analysis of hydrocortisone used in this study showed that the combination of glucocorticoids and AVP had a significant effect on Angs level which eventually causes less endothelial permeability and higher MAP in this group of patients.


PDF Share
  1. Kampmeier TG, Rehberg S, Westphal M, Lange M. Vasopressin in sepsis and septic shock. Minerva Anestesiol 2010;76:844-50.
  2. Farand P, Hamel M, Lauzier F, Plante GE, Lesur O. Review article: Organ perfusion/permeability-related effects of norepinephrine and vasopressin in sepsis. Can J Anaesth 2006;53:934-46.
  3. Gordon A. Vasopressin in septic shock. J Intensive Care Soc 2011;12:11-4.
  4. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228.
  5. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest 2001;120:989-1002.
  6. Boyd JH, Holmes CL, Wang Y, Roberts H, Walley KR. Vasopressin decreases sepsis-induced pulmonary inflammation through the V2R. Resuscitation 2008;79:325-31.
  7. Walley KR. Biomarkers in sepsis. Curr Infect Dis Rep 2013;15:413-20.
  8. Marshall JC. Biomarkers in critical illness: Good answers, but what is the question? J Crit Care 2012;27:519-21.
  9. Nduka OO, Parrillo JE. The pathophysiology of septic shock. Crit Care Clin 2009;25:677-702, vii.
  10. Jekarl DW, Lee SY, Lee J, Park YJ, Kim Y, Park JH, et al. Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis. Diagn Microbiol Infect Dis 2013;75:342-7.
  11. Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci 2013;50:23-36.
  12. Reinhart K, Bauer M, Riedemann NC, Hartog CS. New approaches to sepsis: Molecular diagnostics and biomarkers. Clin Microbiol Rev 2012;25:609-34.
  13. Ng PC, Lam HS. Biomarkers for late-onset neonatal sepsis: Cytokines and beyond. Clin Perinatol 2010;37:599-610.
  14. Rivers EP, Jaehne AK, Nguyen HB, Papamatheakis DG, Singer D, Yang JJ, et al. Early biomarker activity in severe sepsis and septic shock and a contemporary review of immunotherapy trials: Not a time to give up, but to give it earlier. Shock 2013;39:127-37.
  15. Mauri T, Bellani G, Patroniti N, Coppadoro A, Peri G, Cuccovillo I, et al. Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med 2010;36:621-9.
  16. Paulus P, Jennewein C, Zacharowski K. Biomarkers of endothelial dysfunction: Can they help us deciphering systemic inflammation and sepsis? Biomarkers 2011;16 Suppl 1:S11-21.
  17. Moss A. The angiopoietin: Tie 2 interaction: A potential target for future therapies in human vascular disease. Cytokine Growth Factor Rev 2013;24:579-92.
  18. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/SOCIETY of Critical Care Medicine. Chest 1992;101:1644-55.
  19. Russell JA, Walley KR, Gordon AC, Cooper DJ, Hébert PC, Singer J, et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009;37:811-8.
  20. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-63.
  21. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
  22. Reardon DP, DeGrado JR, Anger KE, Szumita PM. Early vasopressin reduces incidence of new onset arrhythmias. J Crit Care 2014;29:482-5.
  23. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-87.
  24. Luckner G, Mayr VD, Jochberger S, Wenzel V, Ulmer H, Hasibeder WR, et al. Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med 2007;35:2280-5.
  25. Dünser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: A retrospective analysis. Anesth Analg 2001;93:7-13.
  26. Andersen TH, Jensen TH, Andersen LW. Adjunctive therapy of severe sepsis and septic shock in adults. Curr Anaesth Crit Care 2009;20:254-8.
  27. Peng TC, Huang CJ. Vasopressin inhibits endotoxin-induced upregulation of inflammatory mediators in activated macrophages. Tzu Chi Med J 2013;25:150-4.
  28. Zhao L, Brinton RD. Suppression of proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha in astrocytes by a V1 vasopressin receptor agonist: A cAMP response element-binding protein-dependent mechanism. J Neurosci 2004;24:2226-35.
  29. Russell JA, Fjell C, Hsu JL, Lee T, Boyd J, Thair S, et al. Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. Am J Respir Crit Care Med 2013;188:356-64.
  30. Russell JA, Walley KR. Vasopressin and its immune effects in septic shock. J Innate Immun 2010;2:446-60.
  31. Heper Y, Akalin EH, Mistik R, Akgöz S, Töre O, Göral G, et al. Evaluation of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock. Eur J Clin Microbiol Infect Dis 2006;25:481-91.
  32. Xing K, Murthy S, Liles WC, Singh JM. Clinical utility of biomarkers of endothelial activation in sepsis – A systematic review. Crit Care 2012;16:R7.
  33. Hall E, Brookes ZL. Angiopoietin-1 increases arteriolar vasoconstriction to phenylephrine during sepsis. Regul Pept 2005;131:34-7.
  34. Bassi E, Park M, Azevedo LC. Therapeutic strategies for high-dose vasopressor-dependent shock. Crit Care Res Pract 2013;2013:654708.
  35. Torgersen C, Luckner G, Schröder DC, Schmittinger CA, Rex C, Ulmer H, et al. Concomitant arginine-vasopressin and hydrocortisone therapy in severe septic shock: Association with mortality. Intensive Care Med 2011;37:1432-7.
  36. Bauer SR, Lam SW, Cha SS, Oyen LJ. Effect of corticosteroids on arginine vasopressin-containing vasopressor therapy for septic shock: A case control study. J Crit Care 2008;23:500-6.
  37. Gordon AC, Mason AJ, Perkins GD, Stotz M, Terblanche M, Ashby D, et al. The interaction of vasopressin and corticosteroids in septic shock: A pilot randomized controlled trial. Crit Care Med 2014;42:1325-33.
  38. Ertmer C, Bone HG, Morelli A, Van Aken H, Erren M, Lange M, et al. Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia. Shock 2007;27:281-8.
  39. Chikanza IC, Petrou P, Chrousos G. Perturbations of arginine vasopressin secretion during inflammatory stress. Pathophysiologic implications. Ann N Y Acad Sci 2000;917:825-34.
  40. Russell JA. Bench-to-bedside review: Vasopressin in the management of septic shock. Crit Care 2011;15:226.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.